Novartis to answer U.S. Senate demand for data manipulation details

ZURICH (Reuters) – Novartis (NOVN.S) plans to answer a U.S. senator who demanded details about data manipulation related to its gene therapy Zolgensma, amid scrutiny of the Swiss drugmaker’s decision to delay informing regulators until after the treatment’s ap... More »